Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Chief Commercial Officer | November 16, 2022 | November 18, 2022 |
| Tricida, Inc.TCDA · Entity 122050 | Chief Comm Officer and Sr VP | July 02, 2018 | July 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date November 16, 2022 · Filed November 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 333,726 |
Reported balance
After 2022-11-16 transaction · row 1
1 source rowRow 1 · 2022-11-16 · Sale · Disposed 16,074 · Balance 333,726 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Tricida, Inc.
Report date July 02, 2018 · Filed July 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,264 |
Reported balance
After 2018-07-02 transaction · row 1
1 source rowRow 1 · 2018-07-02 · Purchase · Acquired 5,264 · Balance 5,264 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2022 Filed Nov 18, 2022 21:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 16,074 | $7.50 | $120,527.67 |
DisclosureSEC source: 0000899243-22-036362 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,726 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 21:53 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 36,592 | $8.20 | $299,904.37 |
DisclosureSEC source: 0000899243-22-035893 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,800 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 4, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:29 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 13,109 | $8.00 | $104,900.84 |
DisclosureSEC source: 0000899243-22-035551 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 4, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:29 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 299 | $8.00 | $2,392.00 |
DisclosureSEC source: 0000899243-22-035551 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,501 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 4, 2022. Read SEC document |
| October 20, 2022 Filed Oct 26, 2022 20:15 UTC Amendment | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,070 | $9.36 | $10,015.95 |
DisclosureSEC source: 0000899243-22-034262 · doc4a.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,800 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2022 Filed Oct 24, 2022 22:26 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,070 | $9.36 | $10,015.95 |
DisclosureSEC source: 0000899243-22-034059 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,800 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:17 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 493 | $7.89 | $3,889.18 |
DisclosureSEC source: 0000899243-22-030423 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,870 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.85 to $7.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:58 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029045 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,363 F3 · shares: The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:58 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,590 | $8.30 | $129,473.39 |
DisclosureSEC source: 0000899243-22-029045 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,363 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.12 to $8.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 23:11 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,058 | $5.21 | $5,516.94 |
DisclosureSEC source: 0000899243-22-026516 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,953 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000899243-22-025233 · doc4.xml · derivative · entry 3 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-07-01 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025233 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,011 F3 · shares: The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| June 03, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 515 | $3.63 | $1,870.53 |
DisclosureSEC source: 0000899243-22-025233 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,011 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"), and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.60 to $3.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 17, 2022 Filed May 18, 2022 12:57 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,262 | $4.40 | $67,166.54 |
DisclosureSEC source: 0000899243-22-018526 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,526 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.31 to $4.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 12:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 852 | $6.68 | $5,695.02 |
DisclosureSEC source: 0000899243-22-015393 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,788 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.665 to $6.6976. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 516 | $9.01 | $4,651.38 |
DisclosureSEC source: 0000899243-22-009059 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,384 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.01 to $9.015. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,322 | $8.32 | $127,525.01 |
DisclosureSEC source: 0000899243-22-007029 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,900 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.15 to $8.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,656 | $8.75 | $40,752.11 |
DisclosureSEC source: 0000899243-22-003004 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,222 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.49 to $9.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 20:22 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 56,744 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0000899243-22-013331 · doc4.xml · derivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,744 Underlying: Common Stock · 56,744 shares Expires 2032-01-18 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 20:22 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 23,256 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013331 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,640 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 21:14 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 514 | $17.06 | $8,770.23 |
DisclosureSEC source: 0000899243-21-046758 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,878 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.79 to $17.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,203 | $21.13 | $321,262.19 |
DisclosureSEC source: 0000899243-21-045272 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,392 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.52 to $21.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 21:58 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,413 | $25.07 | $85,574.83 |
DisclosureSEC source: 0000899243-21-038676 · doc4.xml · nonDerivative · entry 3 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,595 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 21:58 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 12,171 | $25.17 | $306,294.17 |
DisclosureSEC source: 0000899243-21-038676 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,008 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:58 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,000 | $25.04 | $25,036.70 |
DisclosureSEC source: 0000899243-21-038676 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,179 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,916 | $25.08 | $148,362.04 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 7 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,179 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 02, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 513 | $19.86 | $10,188.18 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 6 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,095 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 17, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,205 | $17.82 | $270,953.10 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 5 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,608 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 03, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 508 | $22.87 | $11,617.96 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 4 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,813 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 18, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,201 | $22.80 | $346,582.80 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 3 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,321 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 512 | $37.93 | $19,420.16 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,522 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · balance_after: As previously reported, the reporting person sold 17,100 shares of Common Stock between February 17, 2021 and March 2, 2021. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,600 | $39.21 | $62,732.96 |
DisclosureSEC source: 0001209191-21-017534 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,230 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.075 to $39.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:36 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,332 | $38.62 | $167,300.54 |
DisclosureSEC source: 0001209191-21-017534 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,830 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.06 to $38.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 700 | $40.32 | $28,227.01 |
DisclosureSEC source: 0001209191-21-013485 · doc4.xml · nonDerivative · entry 5 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,162 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.03 to $40.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,418 | $39.18 | $55,556.39 |
DisclosureSEC source: 0001209191-21-013485 · doc4.xml · nonDerivative · entry 4 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,862 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.75 to $39.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,200 | $42.82 | $94,200.92 |
DisclosureSEC source: 0001209191-21-013485 · doc4.xml · nonDerivative · entry 3 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,280 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.42 to $43.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 600 | $41.53 | $24,916.98 |
DisclosureSEC source: 0001209191-21-013485 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,480 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.27 to $41.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,165 | $41.71 | $173,719.65 |
DisclosureSEC source: 0001209191-21-013485 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,080 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.41 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 13:41 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 750 | $41.50 | $31,125.68 |
DisclosureSEC source: 0000899243-21-007332 · doc4.xml · nonDerivative · entry 3 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,245 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.22 to $41.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 13:41 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 800 | $40.44 | $32,349.44 |
DisclosureSEC source: 0000899243-21-007332 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,995 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.22 to $40.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 13:41 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 535 | $39.83 | $21,311.67 |
DisclosureSEC source: 0000899243-21-007332 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.21 to $40.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:20 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 100 | $41.56 | $4,156.00 |
DisclosureSEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 6 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,330 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:20 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,300 | $41.22 | $53,581.84 |
DisclosureSEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 5 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,430 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.56 to $41.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:20 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 400 | $39.72 | $15,887.48 |
DisclosureSEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 4 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,730 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.22 to $40.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 02:20 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 500 | $38.42 | $19,212.00 |
DisclosureSEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 3 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,130 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.20 to $38.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 17, 2021 Filed Sep 20, 2021 22:33 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 15,196 | $39.65 | $602,521.40 |
DisclosureSEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,134 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:20 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 400 | $42.52 | $17,009.00 |
DisclosureSEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,630 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.21 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 02:20 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,700 | $41.76 | $112,760.64 |
DisclosureSEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,030 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.21 to $42.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 48,910 | $41.19 | $2,014,602.90 |
DisclosureSEC source: 0000899243-21-004952 · doc4.xml · nonDerivative · entry 1 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,730 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0000899243-21-002758 · doc4.xml · derivative · entry 2 VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-19 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.